Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803769911> ?p ?o ?g. }
- W2803769911 endingPage "1998" @default.
- W2803769911 startingPage "1987" @default.
- W2803769911 abstract "X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia.In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events.The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every-4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity.In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets. (Funded by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin; ClinicalTrials.gov number, NCT02163577 ; EudraCT number, 2014-000406-35 )." @default.
- W2803769911 created "2018-06-01" @default.
- W2803769911 creator A5000420191 @default.
- W2803769911 creator A5006551650 @default.
- W2803769911 creator A5006764055 @default.
- W2803769911 creator A5009292672 @default.
- W2803769911 creator A5021526213 @default.
- W2803769911 creator A5024283968 @default.
- W2803769911 creator A5034334789 @default.
- W2803769911 creator A5036775753 @default.
- W2803769911 creator A5048702442 @default.
- W2803769911 creator A5051103665 @default.
- W2803769911 creator A5062017015 @default.
- W2803769911 creator A5079265130 @default.
- W2803769911 creator A5082366563 @default.
- W2803769911 creator A5082427336 @default.
- W2803769911 date "2018-05-24" @default.
- W2803769911 modified "2023-10-15" @default.
- W2803769911 title "Burosumab Therapy in Children with X-Linked Hypophosphatemia" @default.
- W2803769911 cites W1964204750 @default.
- W2803769911 cites W1985742682 @default.
- W2803769911 cites W2004997090 @default.
- W2803769911 cites W2019902366 @default.
- W2803769911 cites W2035947437 @default.
- W2803769911 cites W2037559753 @default.
- W2803769911 cites W2043958868 @default.
- W2803769911 cites W2053045761 @default.
- W2803769911 cites W2062515748 @default.
- W2803769911 cites W2065463926 @default.
- W2803769911 cites W2065541106 @default.
- W2803769911 cites W2066145596 @default.
- W2803769911 cites W2075605394 @default.
- W2803769911 cites W2083637886 @default.
- W2803769911 cites W2087333134 @default.
- W2803769911 cites W2090490099 @default.
- W2803769911 cites W2100093237 @default.
- W2803769911 cites W2115247773 @default.
- W2803769911 cites W2115479027 @default.
- W2803769911 cites W2125079553 @default.
- W2803769911 cites W2132689324 @default.
- W2803769911 cites W2139219865 @default.
- W2803769911 cites W2140330355 @default.
- W2803769911 cites W2148823426 @default.
- W2803769911 cites W2159369587 @default.
- W2803769911 cites W2165053324 @default.
- W2803769911 cites W2269306832 @default.
- W2803769911 cites W2316811098 @default.
- W2803769911 cites W2339275496 @default.
- W2803769911 cites W2782092346 @default.
- W2803769911 cites W4211024055 @default.
- W2803769911 cites W4292689881 @default.
- W2803769911 cites W990631582 @default.
- W2803769911 doi "https://doi.org/10.1056/nejmoa1714641" @default.
- W2803769911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29791829" @default.
- W2803769911 hasPublicationYear "2018" @default.
- W2803769911 type Work @default.
- W2803769911 sameAs 2803769911 @default.
- W2803769911 citedByCount "305" @default.
- W2803769911 countsByYear W28037699112018 @default.
- W2803769911 countsByYear W28037699112019 @default.
- W2803769911 countsByYear W28037699112020 @default.
- W2803769911 countsByYear W28037699112021 @default.
- W2803769911 countsByYear W28037699112022 @default.
- W2803769911 countsByYear W28037699112023 @default.
- W2803769911 crossrefType "journal-article" @default.
- W2803769911 hasAuthorship W2803769911A5000420191 @default.
- W2803769911 hasAuthorship W2803769911A5006551650 @default.
- W2803769911 hasAuthorship W2803769911A5006764055 @default.
- W2803769911 hasAuthorship W2803769911A5009292672 @default.
- W2803769911 hasAuthorship W2803769911A5021526213 @default.
- W2803769911 hasAuthorship W2803769911A5024283968 @default.
- W2803769911 hasAuthorship W2803769911A5034334789 @default.
- W2803769911 hasAuthorship W2803769911A5036775753 @default.
- W2803769911 hasAuthorship W2803769911A5048702442 @default.
- W2803769911 hasAuthorship W2803769911A5051103665 @default.
- W2803769911 hasAuthorship W2803769911A5062017015 @default.
- W2803769911 hasAuthorship W2803769911A5079265130 @default.
- W2803769911 hasAuthorship W2803769911A5082366563 @default.
- W2803769911 hasAuthorship W2803769911A5082427336 @default.
- W2803769911 hasBestOaLocation W28037699111 @default.
- W2803769911 hasConcept C114276007 @default.
- W2803769911 hasConcept C124490489 @default.
- W2803769911 hasConcept C126322002 @default.
- W2803769911 hasConcept C134018914 @default.
- W2803769911 hasConcept C197934379 @default.
- W2803769911 hasConcept C2776489590 @default.
- W2803769911 hasConcept C2777288759 @default.
- W2803769911 hasConcept C2778049618 @default.
- W2803769911 hasConcept C2778573388 @default.
- W2803769911 hasConcept C2781208988 @default.
- W2803769911 hasConcept C2911197707 @default.
- W2803769911 hasConcept C519063684 @default.
- W2803769911 hasConcept C71924100 @default.
- W2803769911 hasConcept C90924648 @default.
- W2803769911 hasConceptScore W2803769911C114276007 @default.
- W2803769911 hasConceptScore W2803769911C124490489 @default.
- W2803769911 hasConceptScore W2803769911C126322002 @default.
- W2803769911 hasConceptScore W2803769911C134018914 @default.